ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
Honeysuckle-Derived Nanovesicles Regulate Gut Microbiota for the Treatment of Inflammatory Bowel Disease.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Host metabolism shapes the intestinal microbiota: a top-down paradigm of environmental selection pressure.Gut microbes · 2026Review
- Baicalin alleviates Trueperella pyogenes-induced endometritis with associated changes in gut microbiota composition.BMC veterinary research · 2026Article
- From Multi-Omics to Molecular Causality: A Five-Tier Evidence Framework for the Single-Bacterium-Metabolite Axis in IBD.Microorganisms · 2026Review
- Extracellular Vesicles Derived fromNanomaterials (Basel, Switzerland) · 2026Article
- A DMAHDM-herbal hybrid gargle for orthodontic-associated complications via oral microbiota regulation, inflammation inhibition, and enamel protection.Materials today. Bio · 2026Article
- Past, Present, and Future of Plant-Derived Extracellular Vesicles in Biomedical Applications.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Colon-targeting pH-responsive Bletilla striata polysaccharide coacervate microdroplets for ulcerative colitis therapy via macrophage reprogramming.Journal of nanobiotechnology · 2026Article
- Extremophyte-derived exosome-like nanovesicles remodel intestinal barrier dysfunction by multi-dimensional intervention: physical barrier repair with immune homeostasis and microbiome regulation.Journal of nanobiotechnology · 2026Article
- Cichorium intybus L. polysaccharide improves growth performance and colonic barrier function in weaned piglets via the microbiota-HDCA-TGR5-Akt-NF-κB signaling axis: validation by FMT and in vitro models.Journal of animal science and biotechnology · 2026Article
- Review
- Turmeric-derived nanovesicles reprogram pathological NETosis to mitigate inflammatory bone loss.Journal of nanobiotechnology · 2026Article
- Advances in Nano-Drug Delivery Systems for Chronic Autoimmune Diseases: A Focus on Diabetes Mellitus, Inflammatory Bowel Disease, and Rheumatoid Arthritis.Molecules (Basel, Switzerland) · 2026Review
- Modular design for drug delivery across hierarchical gastrointestinal barriers: From materials to systems.Materials today. Bio · 2026Review
- Engineering Strategies for Plant-Derived Extracellular Vesicles: Modification, Drug Delivery Performance, and Synergistic Effects with Gel Composite Systems.Pharmaceutics · 2026Review
- Integrated multi-omics reveals Enterococcus faecalis JM263 alleviates high-concentrate diet-induced hepatic injury via the gut-liver axis in goats.Microbiome · 2026Article
- Regulatory mechanisms of Traditional Chinese Medicine on gut microbiota in diabetic microvascular complications.Chinese medicine · 2026Review
- Green Nanodrugs: Research Progress and Challenges of Plant-Derived Nanovesicles in Tumor Treatment.Pharmaceutics · 2026Review
- Extracellular Vesicles in Autoimmune Diseases: From Diagnostic Biomarkers to Engineered Therapeutics.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Biomimetic metal-drug coordination nanoplatform to counteract drug resistance in Pseudomonas aeruginosa via energy disruption.Nature communications · 2026Article
- Flos sophorae immaturus exosome-like nanovesicles alleviate ulcerative colitis by attenuating intestinal oxidative stress and inflammation through activating Aryl hydrocarbon receptor via gut microbiota and tryptophan metabolism regulation.Journal of nanobiotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Inflammatory bowel disease (IBD), which includes ulcerative colitis (UC) and Crohn's disease, significantly impairs patients' quality of life and is characterized by a compromised intestinal barrier, pathogenic bacterial colonization, and chronic inflammation. The gut microbiota has emerged as a therapeutic target for IBD owing to its role in modulating immune responses, metabolic pathways, and barrier function. In this study, the therapeutic potential of honeysuckle-derived nanovesicles (HNVs) in a dextran sodium sulfate-induced murine model of UC is investigated. Oral administration of HNVs alleviates colitis symptoms, reduces colonic inflammation and histopathological damage, restores Treg/Th17 balance, and repairs intestinal barrier integrity. These effects are associated with favorable alterations in the gut microbiota, including an increase in beneficial bacteria and a decrease in pathogenic species, along with elevated levels of short-chain fatty acids (SCFAs), which are essential for maintaining mucosal immunity and barrier function. Moreover, metabolomic analysis reveals that HNVs promoted bile acid (BA) absorption and regulated BA metabolism, contributing to the maintenance of intestinal immune homeostasis. Collectively, these findings demonstrate the protective effects of HNVs through modulation of SCFA levels and BA metabolism, supporting their potential as a promising therapeutic strategy for the treatment of IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.